Preemption Argument In Drug/Cosmetic Dispute Likely Falls Short Of Supreme Court
This article was originally published in The Tan Sheet
Executive Summary
Federal law does not preempt Allergan's suit alleging Athena Cosmetics' RevitaLash competes unfairly against the drug firm's Latisse treatment in California, according to a Supreme Court brief filed by Solicitor General Donald Verrilli. Athena argues the absence of FDA action against its eyelash enhancers signals that its cosmetic positioning is lawful.
You may also be interested in...
Neutrogena Pre-emption Defense Stands On California State Court Appeal
The FDA Modernization Act promotes regulatory uniformity and pre-empts litigation seeking changes to J&J/Neutrogena sunscreen labeling claims beyond FDA requirements, a California state appellate court says. OTC drug and cosmetic firms have been less successful with pre-emption arguments in other cases.
Neutrogena Pre-emption Defense Stands On California State Court Appeal
The FDA Modernization Act promotes regulatory uniformity and pre-empts litigation seeking changes to J&J/Neutrogena sunscreen labeling claims beyond FDA requirements, a California state appellate court says. OTC drug and cosmetic firms have been less successful with pre-emption arguments in other cases.
Supreme Court Asked To Consider Pre-emption In Drug Vs. Cosmetic Litigation
The Supreme Court asks the Solicitor General for an amicus in a case examining whether FDA regulation pre-empts state litigation on the cosmetics/drugs regulatory divide. The case could have implications for the personal care industry as states increasingly claim oversight by clarifying FDA’s division between drugs and cosmetics.